Related Experiment Videos
Downregulation of TNF receptor-associated protein-2/p97 in renal cell carcinoma
M J Stassar1, C Pitzer, M Zøller
1Department of Tumor Progression and Immune Defense, German Cancer Research Center, Heidelberg.
Abstract:
Messenger RNA differential display was used to identify genes that are differentially expressed in normal kidney and kidney tumors. We isolated a clone that was uniquely expressed in the normal kidney cell line KCTL-22. The differential expression was confirmed by Northern blot analysis. The cloned cDNA showed 100% homology with type-1 TNF receptor-associated protein-2 (TRAP-2), which is identical to the 97-kDa subunit 2 of the 26S protease (p97). TRAP-2/p97 mRNA was absent or downregulated in two out of four renal cell carcinoma (RCC) lines and in one out of five tissue samples of freshly harvested RCC. All normal tissues tested showed TRAP-2/p97 expression, with highest expression being observed in heart and skeletal muscle. The TRAP-2/p97 mRNA was also detectable in tumor cell lines of nonrenal origin. However, expression levels varied considerably, low levels in particular being observed frequently in malignant melanoma. Although in the tested samples expression of additional subunits of the proteasome, like LMP-2, LMP-7, and LMP-10, were unaltered, the downregulation of TRAP-2/p97 in tumor tissue might affect the processing and presentation of tumor-associated antigens.
Insights
Researchers identified a gene, TRAP-2/p97, crucial for normal kidney cells. This gene was found to be downregulated in some kidney tumors, potentially impacting cancer antigen presentation.
Area of Science:
- Molecular Biology
- Oncology
- Proteasome Function
Background:
- Gene expression profiling is essential for understanding cancer development.
- The 26S proteasome plays a critical role in cellular protein degradation and antigen processing.
Purpose of the Study:
- To identify genes differentially expressed in normal kidney versus kidney tumors.
- To investigate the role of TRAP-2/p97 in renal cell carcinoma (RCC).
Main Methods:
- Messenger RNA (mRNA) differential display to identify gene expression differences.
- Northern blot analysis to confirm differential gene expression.
- cDNA sequencing to identify the cloned gene.
Main Results:
- A clone homologous to TRAP-2/p97 (a subunit of the 26S protease) was identified.
- TRAP-2/p97 mRNA was downregulated or absent in a subset of RCC cell lines and tissues.
- Normal tissues, particularly muscle, showed high TRAP-2/p97 expression, while some non-renal tumors, like melanoma, had low levels.
Conclusions:
- TRAP-2/p97 downregulation in RCC may suggest a role in tumor development.
- Altered TRAP-2/p97 levels could affect tumor-associated antigen processing and presentation.
- Further research is needed to elucidate the precise function of TRAP-2/p97 in kidney cancer.